Effect of aldose reductase inhibitors on glucose-induced changes in sorbitol and myo-inositol metabolism in human neutrophils

Diabetic Medicine

Volumn 16, Issue 1, 1999, Pages 67-73

  Suzuki, K ^a   Kawamura, T ^b   Sakakibara, Fumihiko ^a,d   Sasaki, H ^a   Sano, T ^c   Sakamoto, N ^c   Hotta, N ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Res/Consult Dept of Hlth S   (Japan)

^c CHUBU ROSAI HOSPITAL   (Japan)

^d AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Aldose reductase inhibitor; Myo inositol; Neutrophil; Polyol pathway

Indexed keywords

EPALRESTAT; FIDARESTAT; GLUCOSE; INOSITOL; SORBITOL;

ARTICLE; CELL ACTIVITY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GLUCOSE HOMEOSTASIS; GLYCATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LEUKOCYTE METABOLISM; METABOLIC INHIBITION; NEUTROPHIL;

ADULT; ALDEHYDE REDUCTASE; ENZYME INHIBITORS; HUMANS; IMIDAZOLES; IMIDAZOLIDINES; INOSITOL; LINEAR MODELS; MALE; NEUTROPHILS; REFERENCE VALUES; RHODANINE; SORBITOL; THIAZOLIDINES;

EID: 0032976474     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.1999.00022.x     Document Type: Article

References (37)

1. 1 Gabbay KH. The sorbitol pathway and the complications of diabetes. N Engl J Med 1973; 288: 831-836.
2. 2 Greene DA, Lattimer SA, Ulbrecht J, Carroll P. Glucose-induced alterations in nerve metabolism: current perspective on the pathogenesis of diabetic neuropathy and future directions for research and therapy. Diabetes Care 1985; 8: 290-299.
3. 3 Winegrad AI. Dose a common mechanism induce the diabetic complications of diabetes? Diabetes 1987; 36: 396-406.
4. 4 Sakamoto N, Kinoshita JH, Kador PF, Hotta N (eds). Polyol Pathway and its Role in Diabetic Complications. Amsterdam: Elsevier Science B. V., 1988.
5. 5 Hotta N, Sakamoto N. Aldose reductase inhibitors. In Alberti KGMM and Krall LP, eds. The Diabetes Annual 5. Amsterdam: Elsevier Science B. V., 1990, 330-361.
6. 6 Tomlinson DR, Willars GB, Carrington AL. Aldose reductase inhibitors and diabetic complications. Pharmac Ther 1992; 54: 151-194.
7. 3H]myo-inositol uptake by human, rat and rabbit erythrocytes. Horm Metabol Res 1988; 20: 387-390.
8. +)-ATPase inhibition in aortic wall of rabbits. Diabetologia 1989; 32: 402-408.
9. 9 Takiguchi Y, Wada K, Nakashima M. Effect of aldose reductase inhibitor on the inhibition of platelet aggregation induced by diabetic rat plasma. Eur J Pharmacol 1992; 215: 289-291.
10. 10 Sakakibara F, Hotta N, Koh N, Sakamoto N. Effects of high glucose concentrations and epalrestat on sorbitol and myo-inositol metabolism in cultured rabbit aortic smooth muscle cells. Diabetes 1993; 42: 1594-1600.
11. 11 Wheat LJ. Infection and diabetes mellitus. Diabetes Care 1980; 3: 187-197.
12. 12 Rayfield EJ, Ault MJ, Keusch GT, Brothers MJ, Nechemias C, Smith H. Infection and diabetes: The case of glucose control. Am J Med 1982; 72: 439-450.
13. 13 Bagdade JD, Root RK, Bulger RJ. Impaired leukocyte function in patients with poorly controlled diabetes. Diabetes 1974; 23: 9-15.
14. 14 Wilson RM. Neutrophils function in diabetes. Diabetic Med 1986; 3: 509-512.
15. 15 Leroux JP, Marchand JC, Hong Tuan Ha R, Cartier P. The influence of insulin on glucose permeability and metabolism of human granulocytes. Eur J Biochem 1975; 58: 367-373.
16. 16 Okuno Y, Nishizawa Y, Morii H. Increased insulin-insensitive glucose transport in polymorphonuclear leukocytes from non-insulin dependent diabetic patients. Horm Metab Res 1991; 23: 387-391.
17. 17 Wilson RM, Tomlinson DR, Reeves WG. Neutrophil sorbitol production impairs oxidative killing in diabetes. Diabetic Med 1987; 4: 37-40.
18. 18 Babior BM. Oxygen-dependent microbial killing by phagocytes. N Engl J Med 1978; 298: 659-668.
19. 19 Boland OM, Blackwell CC, Clarke BF, Ewing DJ. Effects of ponalrestat, an aldose reductase inhibitor, on neutrophil killing of Escherichia coli and autonomic function in patients with diabetes mellitus. Diabetes 1993; 42: 336-340.
20. 20 Kashima K, Sato N, Shimizu H, Shimomura Y, Mori M. Effect of Epalrestat on oxygen-deprived free radicals generation by neutrophils from poorly controlled NIDDM patients. Diabetes 1994; 43: 97A.
21. 21 Kawamura T, Suzuki K, Matsumae H, Sano T, Sakamoto N, Hotta N. Effects of glucose and SNK-860, an aldose reductase inhibitor on the polyol pathway and chemiluminescence response of human neutrophils in vitro. Diabet Med 1995; 12: 392-396.
22. 22 Burg MB, Kador PF. Sorbitol, osmoregulation, and the complications of diabetes. J Clin Invest 1988; 81: 635-640.
23. 23 Simmons D, Bomford J, Ng LL. myo-Inositol influx into human leukocytes: methods of measurement and the effect of glucose. Clin Sci 1990; 78: 33-41.
24. 24 Simmons D, Ng LL, Bomford J. Abnormal myoinositol influx in human leukocytes in diabetes but not specifically in diabetic neuropathy. Diabetes 1992; 41: 760-765.
25. 25 Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Scand J Lab Invest 1968; 21: 77-89.
26. 26 Tomiya N, Suzuki T, Awaya J, Mizuno K, Matsubara A, Nakano K et al. Determination of monosaccharides and sugar alcohols in tissues from diabetic rats by high-performance liquid chromatography with pulsed amperometric detection. Anal Biochem 1992; 206: 98-104.
27. 27 Tissot M, Roch Arveiller M, Fontagne J, Giroud JP. Effects of niflumic acid on polyphosphoinositide and oxidative metabolism in poly-morphonuclear leukocytes from healthy and thermally injured rats. Inflammation 1992; 16: 645-657.
28. 28 Ueta F, Osaki T, Kawasaki N, Nomura Y. Suppression of respiratory burst of polymorphonuclear leukocytes by azelastine hydrochloride (Azeptin). Eur J Clin Pharmacol 1994; 47: 139-145.
29. 29 Greene DA, Lattimer SA. Sodium-and energy-dependent uptake of myo-inositol by rabbit peripheral nerve competitive inhibition by glucose and lack of an insulin effect. J Clin Invest 1982; 70: 1009-1018.
30. 30 Li W, Chan LS, Khatami M, Rockey JH. Non-competitive inhibition of myo-inositol transport in cultured bovine retinal capillary pericytes by glucose and reversal by sorbinil. Biochim Biophys Acta 1986; 857: 198-208.
31. 31 Yorek MA, Dunlap JA, Ginsberg BH. myo-Inositol metabolism in 41A3 neuroblastoma cells: effects of high glucose and sorbitol levels. J Neurochem 1987; 48: 53-61.
32. 32 Haneda M, Kikkawa T, Arimura T. Glucose inhibits myo-inositol uptake and reduces myo-inositol content in cultured rat glomerular mesangial cells. Metabolism 1990; 39: 40-45.
33. 33 Olgemöller B, Schwaabe S, Schleicher ED, Gerbitz KD. Competitive inhibition by glucose of myo-inositol incorporation into cultured porcine aortic endothelial cells. Biochim Biophys Acta 1990; 1052: 47-52.
34. 34 Del Monte MA, Rabbni R, Diaz TC, Lattimer SA, Nakamura J, Brennan MC et al. Sorbitol, myo-inositol, and rod outer segment phagocytosis in cultured hRPE cells exposed to glucose. In vitro model of myo-inositol depletion hypothesis of diabetic complications. Diabetes 1991; 40: 1335-1345.
35. 35 Mistry KP, Beyer-Mears AJ, Diecke FPG. Mechanisms for D-glucose inhibition of myo-inositol influx into rat lens. Diabetes 1993; 42: 1737-1744.
36. 36 Finegold D, Lattimer SA, Nolle S, Bernstein M, Greene DA. Polyol pathway activity and myo-inositol metabolism. Diabetes 1983; 32: 988-992.
37. 37 Greene DA, Lattimer SA. Action of sorbinil in diabetic peripheral nerve. Diabetes 1984; 33: 712-716.